Cargando…

p21 in Cancer Research

p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamloo, Bahar, Usluer, Sinem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721478/
https://www.ncbi.nlm.nih.gov/pubmed/31416295
http://dx.doi.org/10.3390/cancers11081178
_version_ 1783448352106479616
author Shamloo, Bahar
Usluer, Sinem
author_facet Shamloo, Bahar
Usluer, Sinem
author_sort Shamloo, Bahar
collection PubMed
description p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor function of p21 is the most studied aspect of this protein in cancer, the role of p21 in phenotypic plasticity and its oncogenic/anti-apoptotic function, depending on p21 subcellular localization and p53 status, have been under scrutiny recently. Basic science and translational studies use precision gene editing to manipulate p21 itself, and proteins that interact with it; these studies have led to regulatory/functional/drug sensitivity discoveries as well as therapeutic approaches in cancer field. In this review, we will focus on targeting p21 in cancer research and its potential in providing novel therapies.
format Online
Article
Text
id pubmed-6721478
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67214782019-09-10 p21 in Cancer Research Shamloo, Bahar Usluer, Sinem Cancers (Basel) Review p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor function of p21 is the most studied aspect of this protein in cancer, the role of p21 in phenotypic plasticity and its oncogenic/anti-apoptotic function, depending on p21 subcellular localization and p53 status, have been under scrutiny recently. Basic science and translational studies use precision gene editing to manipulate p21 itself, and proteins that interact with it; these studies have led to regulatory/functional/drug sensitivity discoveries as well as therapeutic approaches in cancer field. In this review, we will focus on targeting p21 in cancer research and its potential in providing novel therapies. MDPI 2019-08-14 /pmc/articles/PMC6721478/ /pubmed/31416295 http://dx.doi.org/10.3390/cancers11081178 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Shamloo, Bahar
Usluer, Sinem
p21 in Cancer Research
title p21 in Cancer Research
title_full p21 in Cancer Research
title_fullStr p21 in Cancer Research
title_full_unstemmed p21 in Cancer Research
title_short p21 in Cancer Research
title_sort p21 in cancer research
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721478/
https://www.ncbi.nlm.nih.gov/pubmed/31416295
http://dx.doi.org/10.3390/cancers11081178
work_keys_str_mv AT shamloobahar p21incancerresearch
AT usluersinem p21incancerresearch